Ophelia centers on the Ophelia Care Model, a team-based clinical model and software platform developed by experts in addiction medicine and psychiatry. Its clinical protocols include synchronous video-based telehealth visits, FDA-approved medications, urine drug screens, on-demand messaging, optional groups, care coordination services, and treatment for co-occurring psychiatric disorders such as depression and anxiety. Ophelia is licensed to provide care in 27 states and is contracted with Medicaid, Medicare, and commercial insurers covering 75 million American lives. The company intends to use the Series B proceeds to expand its treatment program to more patients and clinicians across the United States, integrate with additional payors and partners, and develop its clinician recruitment, training, and support platform. Led by co-founder and CEO Zack Gray, Ophelia operates a software-enabled, team-based treatment model. Ophelia is a NYC-based healthcare tech startup providing treatment for opioid use disorder via telemedicine. It offers Medication-Assisted Treatment (MAT), combining medication to stop withdrawal and cravings with support and therapy as a private alternative to traditional rehab. Led by co-founder and CEO Zack Gray, the company delivers care through a telemedicine platform for patients who otherwise lack access. Ophelia plans to use recent funding to build and expand its services across the U.S. and to begin accepting insurance, including Medicare and Medicaid. The company raised $15m in a Series A to support that growth. It also added Dr. Darshak Sanghavi to its leadership team to help expand relationships with insurance providers; Sanghavi previously served as Chief Medical Officer at UnitedHealthcare and OptumLabs and as Director of Prevention and Population Health at the Centers for Medicare and Medicaid Services.

Total raised

$65M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2021